Peter Johnson, MD, FACS


  • 30+ years as successful C-suite executive, Chief Medical Officer, and board member, expert in drug and biotech Medical/Scientific/Clinical strategy and management, development/commercialization, funding, and entrepreneurism.

CMO/CEO/Executive Management; Vision and Strategic Planning; Drug Development/Commercialization; Program Creation; Clinical Trials Research, Development, and Management; Medical/Scientific Affairs; SAEs/AEs; New Product R&D and Strategic Planning; Intellectual Property Development; Program/Market Analysis; KOL Engagement; Program Database Development and Data Analysis; Sales and Marketing; Sales Force Development/Management; Venture Capital/Business Development; Recruitment; Communications; Board Membership; Academia (teaching surgery, bioengineering, business administration); Medical/University Administration; and Clinician.
MD – SUNY Health Sciences Center at Syracuse; Residency, General Surgery – University Hospitals of Cleveland; Residency, Plastic Surgery – Hospitals of the University Health Center of Pittsburgh; Fellowship, Thrombosis Research – Department of Surgery, Beth Israel Hospital, Harvard University. Board-certified in General Surgery and in Plastic Surgery. Has nearly 300 presentations, 98 publications, 77 abstracts, 19 book chapters, nine books, and nine patents.
Co-founder and Principal, MedSurgPI, LLC
Provides Medical Science Liaisons, clinical trial support, strategy development, product development, publication planning, and next indication vectoring for the pharmaceutical, biotechnology, and medical device industries.
Vice President, Research and Development, Medical and Scientific Affairs, Vancive Medical Technologies
As member of Executive Leadership Team, led Medical and Scientific Affairs and oversaw Product Technology Innovation client services, new product/intellectual property R&D (including clinical trials), sales support, coordination of R&D innovation, and integration of activities within Medical Quality System. Responsible for R&D policies and participated in R&D strategic planning. Upon transition to consulting Chief Medical Advisor, counseled Medical Affairs staff, supported Marketing in product launches and customer interactions. Sat on the Research Review Committee and served as point of contact for adverse product reactions. Cultivated Key Opinion Leaders, represented Vancive at key meetings, and assisted with clinical trial protocol design, execution, data analysis, and publications.
Executive Vice President and Chief Business Officer, Entegrion, Inc.
Responsible for design and management of rollout of Stasilon, a hemostatic, anti-adherent bandage. Provided decision analysis to assess markets, defined product positioning, optimized geographies for rollout, established and managed a contract sales force, provided systematic strategic planning for the company, assisted CEO in pursuit of financing, and oversaw clinical research and development. Completed development of the initial market penetration plan, sales team development, and initial sales process.
Founder, President, and CEO, Scintellix, LLC
Responsible for the strategic vision and operations of advisory/consulting firm focused on decision analytics for team development, as well as biomedical technology management consulting. Launched joint venture with Headway Corporate Resources to create and manage a life sciences recruiting and staffing division.
Chief Business Officer/Chief Medical Officer, Icoria, Inc.
Responsible for the medical orientation to and oversight of corporate communications and corporate development, including assistance with financing and corporate outreach. Led identification of fusion technologies between the agricultural and health care technology components of the company. Provided overall guidance and execution of revenue generation for sales and marketing.
Co-founder, Chairman, President, and Chief Executive Officer, TissueInformatics, Inc.
Led overall corporate vision, financing, and executive and board management. Raised $25M in multiple rounds of financing prior to merger with Paradigm Genetics in March, 2004.

Subscribe and Follow

Have the latest akta Pharmaceutical Development news delivered right to your inbox. 
And we will never share your information.